Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces the launch of the generic equivalent to Xeloda® (Capecitabine) Tablets, 150 MG and 500 MG, in the United States. Xeloda® is marketed by Genentech in the United States. Teva was the first to receive approval on its ANDA from the U.S. Food and Drug Administration on September 16, 2013 and is launching today per a settlement agreement.
Xeloda® (Capecitabine) Tablets, 150 MG and 500 MG had annual sales of approximately $754 million in the United States, according to IMS data as of December, 2013.
SOURCE Teva Pharmaceutical Industries Ltd.